Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rac-Vorozole SCHEMBL13223107 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| [N-Methyl-11C]Vorozole SCHEMBL12171619 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Rac-Vorozole SCHEMBL29606650 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Vorozole SCHEMBL4554 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Rac-Vorozole SCHEMBL1552681 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Vorozole SCHEMBL19127035 | 0.92 | CYP19A1 (0.84) | CYP19A1CYP11B1 | |
| SCHEMBL13223109 | 0.91 | CYP19A1 (0.83) | CYP19A1CYP11B1 | |
| SCHEMBL13223108 | 0.91 | CYP19A1 (0.83) | CYP19A1CYP11B1 | |
| SCHEMBL3871739 | 0.86 | CYP19A1 (0.76) | CYP19A1CYP11B1 | |
| Oxalic Acid SCHEMBL9524494 | 0.84 | CYP19A1 (0.72) | CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645742-B1 | ANTI-ROR1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20250145573-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER | CKP THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| EP-3139928-B1 | ANORDRIN COMPOSITIONS AND METHODS FOR TREATING DISEASES | SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RES (CN) | 2025-03-05 | — | — | EP | claimed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | claimed |
| US-20240148713-A1 | COMPOSITION FOR TREATMENT OF ANTICANCER DRUG RESISTANCE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2024-05-09 | — | — | US | claimed |
| EP-4295848-A1 | COMPOSITION FOR TREATMENT OF ANTICANCER DRUG RESISTANCE | Industry-Academic Cooperation Foundation, Yonsei University (KR) | 2023-12-27 | — | — | EP | claimed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | claimed |
| EP-3209301-B1 | METHODS OF REDUCING MAMMOGRAPHIC BREAST DENSITY AND/OR BREAST CANCER RISK | HAVAH THERAPEUTICS PTY LTD (AU) | 2023-06-07 | — | — | EP | claimed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| WO-2022177290-A1 | COMPOSITION FOR TREATMENT OF ANTICANCER DRUG RESISTANCE | 연세대학교 산학협력단 | 2022-08-25 | — | — | WO | claimed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | claimed |
| WO-2026106969-A1 | NOVEL INHIBITORS OF INTERLEUKIN RECEPTOR- ASSOCIATED KINASE | UNIVERSITY OF ROCHESTER (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4706684-A2 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | The Regents of The University of Michigan (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4034253-B1 | COMPOSITIONS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | UNIV MICHIGAN REGENTS (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4604947-A2 | COMPOSITIONS AND METHODS FOR PREVENTING CARDIOMYOPATHY | Ohio State Innovation Foundation (US) | 2025-08-27 | — | — | EP | disclosed |
| US-11311538-B2 | Compositions and methods for targeting cancers | YALE UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022055285-A1 | PHARMACEUTICAL COMPOSITION FOR KILLING CANCER PROGENITOR CELLS | 연세대학교 산학협력단 | 2022-03-17 | — | — | WO | disclosed |
| CN-114173814-A | Composition for preventing, ameliorating or treating immune checkpoint inhibitor-resistant cancer | 古德T细胞有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022020661-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 | THE UNIVERSITY OF ROCHESTER (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148713-A1 | COMPOSITION FOR TREATMENT OF ANTICANCER DRUG RESISTANCE | ABCC1, MCL1, SLC11A2 | CYP19A1 985/4885CYP11B1 1836/4885 |
| US-20250145573-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER | ABCC1, BRCA1, TP53 | CYP19A1 1209/4885CYP11B1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.